# Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC

> **NCT05888402** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 50 (estimated)

## Conditions studied

- Local Advanced Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Toripalimab
- **RADIATION:** Concurrent chemoradiation therapy and consolidation immunotherapy

## Key facts

- **NCT ID:** NCT05888402
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-20
- **Primary completion:** 2024-10-08
- **Final completion:** 2026-03-20
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05888402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05888402, "Induction Chemotherapy and Toripalimab Followed by Chemoradiotherapy for Large-volume Local Advanced NSCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05888402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*